Nymox Pharmaceutical Corporation NYMX
Day range unavailable
52-week range unavailable
- Market cap
- 18.24M
- Shares out
- 91.27M
- Beta
- 0.65
- Price target
- 10.25 (+5027.6%)
- Earnings date
- May 12, 2023
Key statistics
- Enterprise value
- 17.87M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -998.04K
- Total cash
- 351.00K
- Total debt
- 114.00K
- Return on equity
- 0.00%
- Short % of float
- 4.65%
- 50-day average
- 0.385079
- 200-day average
- 0.385119
Analyst view
Next earnings
May 12, 2023
Expected May 12, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 1, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 30, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Bahamas
- Website
- nymox.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on NYMX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AVERBACK PAUL | Chief Executive Officer | Sale | Oct 28, 2018 | 21,643,900 |
| DANIELSEN ERIK | Chief Financial Officer | Purchase | Dec 20, 2018 | 20,900 |
| LANHAM RANDALL J ESQ. | General Counsel | Purchase | Oct 25, 2018 | 152,900 |
| ROBINSON JAMES GEORGE | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 26, 2023 | 4,782,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.15% | 135,612 | 27.12K | Mar 30, 2023 |
| Cetera Advisor Networks LLC | 0.13% | 118,900 | 23.78K | Mar 30, 2023 |
| Morgan Stanley | 0.11% | 98,686 | 19.74K | Mar 30, 2023 |
| Simplicity Solutions, LLC | 0.09% | 80,000 | 16.00K | Mar 30, 2023 |
| Bleakley Financial Group, LLC | 0.09% | 80,000 | 16.00K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 0.08% | 69,381 | 13.88K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Micro Cap ETF | 0.12% | 112,238 | 22.45K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 50,678 | 10.13K | Feb 27, 2023 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.01% | 9,318 | 1.86K | Dec 30, 2022 |
| Master Investment Portfolio-Diversified Equity Master Portfolio | 0.01% | 5,685 | 1.14K | Dec 30, 2022 |